In this review we aim to provide both an overview of the diagnosis and recent advances in the management of narcolepsy and cataplexy, and an insight into the impact that this condition has on children and their families.
Definition
Narcolepsy is a lifelong incurable neurological condition affecting the regulation of normal sleep/wake cycles. Excessive daytime sleepiness (EDS) and attacks of muscle weakness which are often precipitated by strong emotions (cataplexy) are hallmarks of the disorder. Dysregulation of sleep/wake can lead to fragmented night-time sleep in association with hypnagogic and hypnopompic hallucinations, vivid nightmares and sleep paralysis.
Prevalence
The prevalence of narcolepsy is estimated to be 20-50 per 100,000 population, around a quarter of the prevalence of multiple sclerosis. Historically, the prevalence was underestimated, with early studies reporting a median delay of 10 years between symptom onset and diagnosis. With increased understanding and recognition of the condition this is improving. The disorder most commonly starts in the teens but around 8% present before the age of 5 years. A family history is uncommon In the 1980s, a search for potential narcolepsy genes revealed that the tissue type HLA-DQB1*0602
is present in 95% people with both narcolepsy and cataplexy and 40% people with narcolepsy without cataplexy, suggesting that an autoimmune process may have a role in the disorder.
However, the frequency of the gene in the general population of 18-35% indicated that other factors had to be involved to produce narcolepsy.
The most recent breakthrough in the 1990s was the discovery of a peptide neurotransmitter found in the hypothalamus. The peptide was discovered simultaneously by two independent research groups, one of which named it orexin (as it stimulated appetite in rats) and the other hypocretin (as it was found in the hypothalamus and resembled secretin). The peptide plays a role in stabilisation of the transition between wake and sleep states. Reduced concentrations of hypocretin in the cerebrospinal fluid (CSF) in humans with narcolepsy and cataplexy suggest that the condition is caused by a deficiency in hypocretin production and that hypocretin producing cells may be destroyed by an autoimmune process in HLA-associated narcolepsy.
Triggers to this autoimmune process are often infections. Antibodies to the primary trigger are formed which share similar properties to hypocretin producing cells in the hypothalamus, resulting 
Cataplexy
Symptoms of cataplexy range from jaw dropping, to weakness at the knees, to total collapse. At disease onset, the cataplexy symptoms may be more subtle, with drooping of the eyelids or lolling of T c pointing to other differential diagnoses such as myasthenia. Cataplexy is usually triggered by strong emotions such as laughter, anger and surprise and may last between a few seconds and several minutes. The loss of muscle tone is bilateral and the child retains awareness throughout the episode.
Home videos of these episodes may aid in confirmation of the diagnosis.
REM intrusion
Disrupted nocturnal sleep is frequently associated with vivid nightmares due to REM intrusion.
Hypnagogic/hypnopompic hallucinations (vivid, dream-like experiences at the start/end of sleep), occur in 39-50% children with narcolepsy and are often emotionally disturbing and difficult to distinguish from reality. More unusual symptoms associated with narcolepsy include sleep paralysis (inability to move for a minute or two at the beginning or end of sleep due to persisting REM atonia), confusional arousals and automatic behaviour (the continued error prone performance of a task at a time of mounting sleepiness).
Obesity
Narcolepsy can be associated with precocious puberty, and obesity and is a feature in up to 84% of children with narcolepsy, despite lower calorie intake, often manifesting prior to diagnosis. The mechanism of weight gain is not clear but may be related to abnormal hypocretin and leptin levels leading to impaired energy metabolism. Parents may report an increase in snacking which can be difficult to control and leads to further confrontation with their child.
Referral to a sleep centre and shared care
If the history suggests a true EDS need with no underlying cause for nocturnal sleep disturbance and/or intermittent muscle weakness in response to emotional triggers, a referral to a specialist sleep centre is recommended for confirmation of the diagnosis. After diagnosis, a review at least annually by a specialist familiar with the condition and evolving treatments is a proposed model of care.
Diagnostic Investigations
Investigations recommended for confirmation of the diagnosis of narcolepsy and cataplexy are as follows:
 Actigraphy and sleep diary  Polysomnography (PSG) and Multiple Sleep Latency Testing (MSLT)
 CSF and blood analysis
Actigraphy and sleep diary
Actigraphy is a quantitative method of recording motor activity during sleep and wake and is a useful screening method to exclude sleep pattern disorders. A two week period of actigraphy with a sleep diary is recommended as part of the diagnostic process to exclude other primary sleep disorders and sleep hygiene problems.
Overnight polysomnography
Polysomnography is a multi-channel physiological test to monitor sleep patterns, breathing, gas [1] Sleep onset latency (SOL) -the time it takes to fall asleep.
[2] The presence or absence of REM sleep during each nap, known as the frequency of sleep onset REM periods (SOREMPs). 
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impairments in decision-making, concentration and learning. It is particularly important to understand the impact of narcolepsy on cognitive function in school-age children so that the children are provided with the most effective support to enable them to achieve their full potential.
A systematic review of cognitive function and psychosocial well-being in school-age children with narcolepsy found that this group are at particular risk of cognitive impairment in at least one domain (e.g. decision making, verbal IQ, performance IQ), however a consistent pattern of impairment was not found across the studies. The most commonly reported problems were persistent sleepiness, lack of alertness and lack of concentration which are likely to impact on cognitive function and may be the underlying cause of the high levels of academic failure reported in the children. Management is pharmacological and non-pharmacological. Drug management is usually initiated and monitored by a specialist centre following diagnosis, however lifestyle management and support is essential and can be best provided by local clinicians with whom the patient is familiar. The specialist centre should take a multidisciplinary team (MDT) approach with input from experts in narcolepsy who can liaise with school, local clinicians and GPs, local pharmacy and the family.
Specialist teams frequently comprise: clinicians, nurses, pharmacist, physiologist, psychologist and a transition arrangement to an adult narcolepsy service. Attention to sleep hygiene and planned naps can be used to optimise daytime performance. Relevant and accurate information should be made available to the patient, relatives and schools, as well as medical professionals unfamiliar with the condition. Information and support provided by the charity Narcolepsy UK (www.narcolepsy.org.uk) is extremely useful and recommended highly by most families. Weight management is important in preventing complications of obesity. Children should be encouraged to take part in sports activities and an exercise program may have a stimulating effect.
Driving
In the United Kingdom, people with narcolepsy are required by law to inform the Driver and Vehicle Licensing Authority (DVLA) about the diagnosis and are generally advised to refrain from driving until the DVLA has reached a decision on their case. Holders of ordinary group 1 licences will be permitted colepsy are generally considered unfit to hold group 2 (heavy goods vehicle and bus) licences, although exceptions can be made.
School
This account has been written by a teenager with narcolepsy who has recently experienced the rigours of GCSE exams whilst coping with severe narcolepsy symptoms: suggests it is also effective in post-pubertal children (combined n=23), however, it is not licensed for use in children. Sodium oxybate should only be initiated following an MDT discussion, which should include psychological assessment where the child is deemed to be at higher risk of harm.
Coping Strategies for School
Future Research
The advances in understanding the pathophysiology of narcolepsy in recent years has led to novel approaches to narcolepsy treatment. Immunomodulation has been proposed as a potential therapeutic option; however, trials have had mixed results and none has reversed the disease process.
Recent results suggest a T-cell rather than B-cell/antibody mediation. Medications targeting T-cells (e.g., alpha-4 integrin inhibitors blocking T cell entry to the brain, such as natalizumab) may therefore have more beneficial effects.
A trial of hypocretin replacement therapy using intranasal administration of hypocretin-1 is currently under evaluation. Central administration of hypocretin-1 reverses narcolepsy in animal models, but unfortunately the hypocretin peptide does not cross the blood brain barrier. Studies are needed to fully evaluate this therapy, including its potential for use in the paediatric population.
A randomized, double-blind clinical trial of pitolisant, an H3 receptor inverse agonist has shown promising results in adults and adolescents. Further stimulant options including caffeine, benzodiazepines and baclofen have been used on a case by case basis but have not been evaluated in formal trials.
In general both pharmacological and non-pharmacological interventions, including exercise and cognitive behavioural therapies require systematic evaluation, especially in young children. In addition, further education of the medical profession and the public is needed to minimise the impact of this debilitating condition and ultimately to improve prognosis and outcomes for children and adolescents presenting with narcolepsy with cataplexy. 
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